Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hospices Civils de Lyon
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Postmenopausal women (more than one year since last menstrual period or removal of ovarian function by surgical or radiotherapic means)
Operated for an invasive breast cancer (histologically proven)
Surgical treatment completed and cycles of adjuvant chemotherapy (if necessary) completed
Treated with aromatase inhibitor
Osteopenic (-2.5\<T score\<-1) without osteoporotic fracture
With written informed consent signed
With social security
You may not be if
Women presenting a history of osteoporotic fracture or a T score less than -2.5 at at least one measure site
Women presenting clinical signs of metastases
Having received other hormonal treatment in the last 3 months
Having received treatment by bisphosphonates, raloxifene, tamoxifen, parathormone, strontium ranelate, tibolone,calcitonin and corticosteroids at more than 5mg/d for 3 months in the last year
Presenting a known and untreated hyperthyroid
Presenting a known hyperadrenocorticism
Patients treated and followed for Paget's disease of bone
Presenting a untreated primary hyperparathyroid
Presenting an indication against risedronate (known hypersensibility to risedronate monosodium and/or one of its excipients, non-corrected hypocalcemia, pregnancy or breast feeding, severe renal insufficiency inferior to 30 ml/min)
Patients presenting malabsorption syndrome for glucose/galactose
Person participating in another clinical trial concerning a medicine susceptible to influence bone mass
Clareo Health | Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer
